» Articles » PMID: 26519292

FDG PET/CT in Cancer: Comparison of Actual Use with Literature-based Recommendations

Abstract

Purpose: The Region of Southern Denmark (RSD), covering 1.2 of Denmark's 5.6 million inhabitants, established a task force to (1) retrieve literature evidence for the clinical use of positron emission tomography (PET)/CT and provide consequent recommendations and further to (2) compare the actual use of PET/CT in the RSD with these recommendations. This article summarizes the results.

Methods: A Work Group appointed a professional Subgroup which made Clinician Groups conduct literature reviews on six selected cancers responsible for 5,768 (62.6 %) of 9,213 PET/CT scans in the RSD in 2012. Rapid Evidence Assessment was applied, using the methodology of systematic reviews with predefined limitations to search PubMed, Embase and the Cochrane Library for articles published in English/Danish/Swedish/Norwegian since 2002. PICO questions were defined, data recorded and quality appraised and rated with regard to strength and evidence level. Consequent recommendations for applications of PET/CT were established. The actual use of PET/CT was compared with these, where grades A and B indicated "established" and "useful" and grades C and D "potentially useful" and "non-recommendable" indications, respectively.

Results: Of 11,729 citations, 1,729 were considered for review, and 204 were included. The evidence suggested usefulness of PET/CT in lung, lymphoma, melanoma, head and neck, and colorectal cancers, whereas evidence was sparse in gynaecological cancers. The agreement between actual use of PET/CT and literature-based recommendations was high in the first five mentioned cancers in that 96.2 % of scans were made for grade A or B indications versus only 22.2 % in gynaecological cancers.

Conclusion: Evidence-based usefulness was reported in five of six selected cancers; evidence was sparse in the sixth, gynaecological cancers. Actual use of PET/CT agreed well with recommendations.

Citing Articles

Optimizing Low-Dose [18F]FDG-PET/CT Scans: Ensuring Quality Amid Radiotracer Availability Challenges - Insights from a Peripheral Tertiary Care Center.

Tayal S, Jain Y, Thakur S, Shukla V, Venkatachalam M, Kumar A Indian J Nucl Med. 2025; 39(4):292-298.

PMID: 39790828 PMC: 11708796. DOI: 10.4103/ijnm.ijnm_90_24.


Use of [F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography after Curative Treatment of Non-Small-Cell Lung Cancer Patients: A Nationwide Cohort Study.

Guldbrandsen K, Sopina L, Rasmussen T, Fischer B Diagnostics (Basel). 2024; 14(2).

PMID: 38275480 PMC: 10814487. DOI: 10.3390/diagnostics14020233.


FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects.

Al-Ibraheem A, Abdlkadir A, Juweid M, Al-Rabi K, Makoseh M, Abdel-Razeq H Cancers (Basel). 2023; 15(4).

PMID: 36831405 PMC: 9954669. DOI: 10.3390/cancers15041063.


PET/MR versus PET/CT for locoregional staging of oropharyngeal squamous cell cancer.

Flygare L, Erdogan S, Soderkvist K Acta Radiol. 2022; 64(5):1865-1872.

PMID: 36464816 PMC: 10160406. DOI: 10.1177/02841851221140668.


Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.

Ferrari C, Maggialetti N, Masi T, Nappi A, Santo G, Niccoli Asabella A J Pers Med. 2021; 11(3).

PMID: 33803667 PMC: 8002936. DOI: 10.3390/jpm11030217.


References
1.
Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A . Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009; 361(1):32-9. DOI: 10.1056/NEJMoa0900043. View

2.
Xing Y, Bronstein Y, Ross M, Askew R, Lee J, Gershenwald J . Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2010; 103(2):129-42. PMC: 3022618. DOI: 10.1093/jnci/djq455. View

3.
Hess S, Blomberg B, Zhu H, Hoilund-Carlsen P, Alavi A . The pivotal role of FDG-PET/CT in modern medicine. Acad Radiol. 2014; 21(2):232-49. DOI: 10.1016/j.acra.2013.11.002. View

4.
Schroer-Gunther M, Wolff R, Westwood M, Scheibler F, Schurmann C, Baumert B . F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev. 2012; 1:62. PMC: 3536719. DOI: 10.1186/2046-4053-1-62. View

5.
Maas M, Rutten I, Nelemans P, Lambregts D, Cappendijk V, Beets G . What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis : imaging for recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2011; 38(8):1560-71. PMC: 3126998. DOI: 10.1007/s00259-011-1785-1. View